An Introduction to Multiple Sclerosis
Multiple sclerosis (MS) is an immune-mediated inflammatory demyelinating disease of the CNS and one of the most common causes of neurological disability in adults. It is characterized by a relapsing-remitting clinical course, which progresses to a more chronic progressive phase, although a minority have a progressive course from onset. Numerous disease-modifying therapies (DMTs) have emerged, including oral (fingolimod, dimethyl fumarate, teriflunomide, cladribine, siponimod, ozanimod), injectable (glatiramer acetate, pegylated interferon beta-1a) and intravenous (alemtuzumab, ocrelizumab) options. Challenges include switching therapies in patients who become refractory to initial treatment. MS is also the fastest growing indication for autologous haematopoietic stem cell transplantation in Europe, with a growing body of evidence supporting its use in highly active relapsing-remitting MS that does not respond to DMTs.
Browse video highlights and short articles from the conference hub, providing insights into the latest updates from major conferences and peer-reviewed articles from the journal portfolio. This is complimented by a range of educational activities from our expert faculty, with patient outcomes at the forefront.
Multiple Sclerosis Content
Advances in the Treatment of Neuromyelitis Optica Spectrum Disorders
US Neurology. 2020;16(1):38–42 DOI: https://doi.org/10.17925/USN.2020.16.1.38
Neuromyelitis optica spectrum disorder (NMOSD) refers to a family of inflammatory central nervous system (CNS) diseases in which patients accrue disability through severe episodes of demyelination with typical manifestations including involvement of visual pathways (e.g., optic neuritis) and spinal cord (longitudinally extensive myelitis). Other common symptoms, including intractable hiccups, nausea and vomiting are also well […]
Sean Pittock, EAN 2020 – Phase 3 PREVENT Study Insights in Neuromyelitis Optica Spectrum Disorder
Sean Pittock (Mayo Clinic College of Medicine, Rochester, MN, USA) shared with us his expert insights from the phase 3 PREVENT study, a randomized controlled trial of eculizumab in AQP4 antibody-positive participants with neuromyelitis optica (ClinicalTrials.gov Identifier: NCT01892345), including a sub analysis he presented on eculizumab monotherapy. Questions 1. Could you give us an overview […]
Xavier Montalban, EAN 2020 – Long-term Phase II Outcomes of First Oral BTK Inhibitor in MS
Xavier Montalban (St Michael’s Hospital, University of Toronto, Toronto, Canada and Vall d’Hebron University Hospital, Barcelona, Spain) shares his expert insights on the rationale for the use of evobrutinib, a Bruton’s tyrosine kinase (BTK) inhibitor, in the treatment of patients with relapsing multiple sclerosis (MS), as well as an overview of key efficacy and safety […]
Celia Oreja-Guevara, EAN 2020 – Regional Findings From The Phase 3 PREVENT Study in NMOSD
Great to have an opportunity to speak with Celia Oreja-Guevara (University Hospital San Carlos and University Complutense, Madrid, Spain) around the highlights of her presentation entitled: Regional outcomes of eculizumab treatment in patients with aquaporin-4 immunoglobin G-positive neuromyelitis optica spectrum disorder: findings from the phase 3 PREVENT study (ClinicalTrials.gov Identifier: NCT01892345). Questions 1. What were […]
Bianca Weinstock-Guttman, EAN 2020 – CHORDS Study in RRMS With Suboptimal Prior Response to DMTs
Bianca Weinstock-Guttman (Jacobs School of Medicine and Biomedical Science, University of Buffalo, NY, USA) shares highlights of her presentation entitled: Effectiveness and safety of ocrelizumab in patients with relapsing-remitting multiple sclerosis who had a suboptimal response with prior disease-modifying therapy: 2-year findings from CHORDS (ClinicalTrials.gov Identifier: NCT02637856). Questions 1. What are the potential advantages of […]
Andrew Chan, EAN 2020 – COVID-19 and Multiple Sclerosis
Great to catch-up with Andrew Chan (Inselspital Bern, University Hospital, University of Bern, Bern, Switzerland), who discussed challenges posed to patient care by COVID-19, factors to consider around immunosuppression for patients with multiple sclerosis (MS) during the pandemic, as well his personal thoughts on exciting developments in MS therapy and the 1st Virtual EAN Congress. […]
How do we personalize treatment of multiple sclerosis in the light of recent advances?
Watch leading experts involved in the care of patients with multiple sclerosis discuss how recent advances in understanding of MS pathophysiology may drive treatment choices, now and in the future.
- Recall the disease mechanisms contributing to the progression of MS
- Interpret the role of induction therapy in real-world clinical practice
- Recognize the importance of BTK as a potential future treatment target in MS
EAN 2020 – Time for Action. Predict. Prevent. Repair.
EAN President, Prof. Claudio Bassetti invites you to participate in the EAN 2020 congress. You can register for the virtual congress free-of-charge here. It’s a fantastic opportunity for everyone in the neurology community to benefit from the possibility of education, scientific news and best practice exchange from the comfort of home. Be sure to visit our EAN […]
Ofatumumab – A Potential Subcutaneous B-cell Therapy for Relapsing Multiple Sclerosis
European Neurological Review. 2020;15(1):Epub ahead of publication
Multiple sclerosis (MS) has traditionally been considered a primarily T-cell-mediated autoimmune disease of the central nervous system (CNS); this is based on data from animal models,1 the presence of activated T lymphocytes in MS plaques that outnumber B cells and T-cell subset alterations in blood,2 the association of MS with certain human leukocyte antigen (HLA) and a […]
Journal articles and more to your inbox
Get the latest clinical insights from touchNEUROLOGYSign me up!